Satralizumab
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD).[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | interleukin 6 receptor |
| Clinical data | |
| Trade names | Enspryng |
| Other names | SA237, sapelizumab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6340H9776N1684O2022S46 |
| Molar mass | 143416.47 g·mol−1 |
This drug is being developed by Chugai Pharmaceutical, a member of the Roche Group.[2] The efficacy and safety of Satralizumab has been tested in two phase III clinical trials in patients with diagnosed neuromyelitis optica.[3]
Satralizumab has been approved for the treatment of AQP4-IgG-seropositive NMOSD in Canada, Japan, and Switzerland.[4]
Names
Satralizumab is the International Nonproprietary Name (INN)[5]
gollark: Also the NSA. They have datas.
gollark: Yes, even osmarks.tk™ has access to all that.
gollark: Also Intel, once they use the Management Engine to get access to every modern Intel computer on the planet and steal all their classified data. They can totally do that.
gollark: Yes, probably the military contractors.
gollark: I mean, the big tech companies around now are Facebook, Apple, Amazon, Google, Microsoft, and to be honest probably some random Chinese ones I don't really know about.
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab, American Medical Association.
- "Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018".
- "compendium.ch". compendium.ch (in German). 2020-07-08. Retrieved 2020-08-10.
- "Enspryng (satralizumab)". Roche. Retrieved 9 August 2020.
- World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3): 552. hdl:10665/330961. License: CC BY-NC-SA 3.0 IGO.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.